The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Arming antibodies: prospects and challenges for immunoconjugates
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Self-citationDevelopment of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Self-citationFrancisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
Self-citationApproval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 629
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates
Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellström, I., & Hellström, K. E. (1993) · Science · doi:10.1126/science.8327892 · Cited by 556
Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., & Trail, P. A. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025536j · Cited by 555
Sievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., Shannon-Dorcy, K., Berger, M. S., & Bernstein, I. D. (1999) · Blood · doi:10.1182/blood.v93.11.3678 · Cited by 512
Antigen-specific human antibodies from mice comprising four distinct genetic modifications
Lonberg, N., Taylor, L. D., Harding, F. A., Trounstine, M., Higgins, K. M., Schramm, S. R., Kuo, C.-C., Mashayekh, R., Wymore, K., McCabe, J. G., et al. (1994) · Nature · doi:10.1038/368856a0 · Cited by 398
Efficient Cancer Therapy with a Nanobody-Based Conjugate
Cortez-Retamozo, V., Backmann, N., Senter, P. D., Wernery, U., De Baetselier, P., Muyldermans, S., & Revets, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3935 · Cited by 382
Self-citationAntibody-targeted radiation cancer therapy
Milenic, D. E., Brady, E. D., & Brechbiel, M. W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1413 · Cited by 380
DiJoseph, J. F., Armellino, D. C., Boghaert, E. R., Khandke, K., Dougher, M. M., Sridharan, L., Kunz, A., Hamann, P. R., Gorovits, B., Udata, C., et al. (2004) · Blood · doi:10.1182/blood-2003-07-2466 · Cited by 361
Green, L. L., Hardy, M. C., Maynard-Currie, C. E., Tsuda, H., Louie, D. M., Mendez, M. J., Abderrahim, H., Noguchi, M., Smith, D. H., Zeng, Y., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-13 · Cited by 355
Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A., Leprini, A., Sepulveda, J., Burrone, O., Neri, D., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10662 · Cited by 355
In-vitro protein evolution by ribosome display and mRNA display
Lipovsek, D., & Plückthun, A. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.04.008 · Cited by 353
Santimaria, M., Moscatelli, G., Viale, G. L., Giovannoni, L., Neri, G., Viti, F., Leprini, A., Borsi, L., Castellani, P., Zardi, L., et al. (2003) · PubMed · Cited by 335
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors
Smith-Jones, P. M., Solit, D. B., Akhurst, T., Afroze, F., Rosen, N., & Larson, S. M. (2004) · Nature Biotechnology · doi:10.1038/nbt968 · Cited by 304
Waibel, R., Alberto, R., Willuda, J., Finnern, R., Schibli, R., Stichelberger, A., Egli, A., Abram, U., Mach, J.-P., Plückthun, A., et al. (1999) · Nature Biotechnology · doi:10.1038/12890 · Cited by 303
Giles, F. J., Kantarjian, H. M., Kornblau, S. M., Thomas, D. A., Garcia-Manero, G., Waddelow, T. A., David, C. L., Phan, A. T., Colburn, D. E., Rashid, A., et al. (2001) · Cancer · doi:10.1002/1097-0142(20010715)92:2<406::aid-cncr1336>3.0.co;2-u · Cited by 283
Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
Dubowchik, G. M., & Walker, M. A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00018-2 · Cited by 277
Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Flowers, D. A., & Bernstein, I. (2002) · Bioconjugate Chemistry · doi:10.1021/bc0100206 · Cited by 230
Sundaresan, G., Yazaki, P. J., Shively, J. E., Finn, R. D., Larson, S. M., Raubitschek, A. A., Williams, L. E., Chatziioannou, A. F., Gambhir, S. S., & Wu, A. M. (2003) · PubMed · Cited by 222
Self-citationLinenberger, M. L. (2005) · Leukemia · doi:10.1038/sj.leu.2403598 · Cited by 214
Natural and designer binding sites made by phage display technology
Hoogenboom, H. R., & Chames, P. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01667-4 · Cited by 213
Immunotoxins: magic bullets or misguided missiles?
Vitetta, E. S., Thorpe, P. E., & Uhr, J. W. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90041-i · Cited by 207
Tolcher, A. W., Ochoa, L., Hammond, L. A., Patnaik, A., Edwards, T., Takimoto, C., Smith, L., de Bono, J., Schwartz, G., Mays, T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.137 · Cited by 206 · cited 1×
“A subsequent phase II trial confirmed that the response rate was low, although it was noteworthy that active drug could be detected within tumor masses that had undergone biops”
BackgroundKenanova, V., Olafsen, T., Crow, D. M., Sundaresan, G., Subbarayan, M., Carter, N. H., Ikle, D. N., Yazaki, P. J., Chatziioannou, A. F., Gambhir, S. S., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.622.65.2 · Cited by 206
Self-citationPerspectives on cancer therapy with radiolabeled monoclonal antibodies.
Sharkey, R. M., & Goldenberg, D. M. (2005) · PubMed · Cited by 200
Saleh, M. N., Sugarman, S., Murray, J., Ostroff, J. B., Healey, D., Jones, D., Daniel, C. R., LeBherz, D., Brewer, H., Onetto, N., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2282 · Cited by 196
Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.
Saga, T., Neumann, R. D., Heya, T., Sato, J., Kinuya, S., Le, N., Paik, C. H., & Weinstein, J. N. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8999 · Cited by 191
Dubowchik, G. M., & Firestone, R. A. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00609-x · Cited by 188
Selective activation of anticancer prodrugs by monoclonal antibody–enzyme conjugates
Senter, P. D., & Springer, C. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00206-x · Cited by 178
Self-citationRobinson, M. K., Doss, M., Shaller, C., Narayanan, D., Marks, J. D., Adler, L. P., González Trotter, D. E., & Adams, G. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2008 · Cited by 169
Francis, R. J., Sharma, S. K., Springer, C., Green, A. J., Hope-Stone, L. D., Sena, L., Martin, J., Adamson, K. L., Robbins, A., Gumbrell, L., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600517 · Cited by 163
Henry, M. D., Wen, S., Silva, M. D., Chandra, S., Milton, M., & Worland, P. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1722 · Cited by 156
Optimizing Radiolabeled Engineered Anti-p185HER2 Antibody Fragments for In vivo Imaging
Olafsen, T., Kenanova, V. E., Sundaresan, G., Anderson, A.-L., Crow, D. M., Yazaki, P. J., Li, L., Press, M. F., Gambhir, S. S., Williams, L. E., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4472 · Cited by 156
Self-citationAntibody-targeted chemotherapy with immunoconjugates of calicheamicin
Damle, N. K. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00083-3 · Cited by 155
Yeast display of antibody fragments: a discovery and characterization platform
Feldhaus, M. J., & Siegel, R. W. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.04.009 · Cited by 155
Thorpe, P. E., Wallace, P. M., Knowles, P. P., Relf, M., Brown, A. N., Watson, G., Blakey, D. C., & Newell, D. R. (1988) · PubMed · Cited by 155
Forero, A., Weiden, P. L., Vose, J. M., Knox, S. J., LoBuglio, A. F., Hankins, J. H., Goris, M. L., Picozzi, V. J., Axworthy, D. B., Breitz, H. B., et al. (2004) · Blood · doi:10.1182/blood-2003-09-3284 · Cited by 155
Doussal, J. M. L., Martin, M., Gautherot, E., DELAAGE, M. A., & Barbet, J. (1989) · PubMed · Cited by 153
Xie, H., Audette, C. A., Hoffee, M., Lambert, J. M., & Blättler, W. A. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060533 · Cited by 142
Weiden, P. L., Breitz, H. B., Press, O. W., Appelbaum, J. W., Bryan, J. K., Gaffigan, S., Stone, D. M., Axworthy, D. B., Fisher, D. R., & Reno, J. M. (2000) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2000.15.15 · Cited by 141
A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy.
Schultz, J., Lin, Y., Sanderson, J., Zuo, Y., Stone, D. M., Mallett, R. W., Wilbert, S. M., & Axworthy, D. B. (2000) · PubMed · Cited by 127
Tassone, P., Goldmacher, V. S., Neri, P., Gozzini, A., Shammas, M. A., Whiteman, K. R., Hylander-Gans, L., Carrasco, D. R., Hideshima, T., Shringarpure, R., et al. (2004) · Blood · doi:10.1182/blood-2004-03-0963 · Cited by 124
Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods
Sharkey, R. M., Karacay, H., Cardillo, T. M., Chang, C., McBride, W. J., Rossi, E. A., Horak, I. D., & Goldenberg, D. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1004-0009 · Cited by 121
Yazaki, P. J., Wu, A. M., Tsai, S.-W., Williams, L. E., Iklé, D. N., Wong, J. Y. C., Shively, J. E., & Raubitschek, A. A. (2001) · Bioconjugate Chemistry · doi:10.1021/bc000092h · Cited by 116
Self-citationEfficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates
Law, C., Cerveny, C. G., Gordon, K. A., Klussman, K., Mixan, B. J., Chace, D. F., Meyer, D. L., Doronina, S. O., Siegall, C. B., Francisco, J. A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1028 · Cited by 116
Self-citationOlafsen, T., Cheung, C. W., Yazaki, P. J., Li, L., Sundaresan, G., Gambhir, S. S., Sherman, M. A., Williams, L. E., Shively, J. E., Raubitschek, A. A., et al. (2004) · Protein Engineering Design and Selection · doi:10.1093/protein/gzh009 · Cited by 114
Self-citationWong, J. Y. C., Shibata, S., Williams, L. E., Kwok, C. S., Liu, A., Chu, D. Z. J., Yamauchi, D. M., Wilczynski, S. P., Iklé, D. N., Wu, A. M., et al. (2003) · PubMed · Cited by 97
Self-citationIrving, R. A., Coia, G., Roberts, A., Nuttall, S. D., & Hudson, P. J. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00341-0 · Cited by 96
Olafsen, T., Tan, G., Cheung, C. W., Yazaki, P. J., Park, J. M., Shively, J. E., Williams, L. E., Raubitschek, A. A., Press, M. F., & Wu, A. M. (2004) · Protein Engineering Design and Selection · doi:10.1093/protein/gzh040 · Cited by 88
Self-citationAdams, G. P., Shaller, C. C., Dadachova, E., Simmons, H. H., Horak, E. M., Tesfaye, A., Klein–Szanto, A. J., Marks, J. D., Brechbiel, M. W., & Weiner, L. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2382 · Cited by 87
Adams, G. P., Shaller, C. C., Chappell, L. L., Wu, C., Horak, E. M., Simmons, H. H., Litwin, S., Marks, J. D., Weiner, L. M., & Brechbiel, M. W. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00103-7 · Cited by 84
Mayer, A., Sharma, S. K., Tolner, B., Minton, N. P., Purdy, D., Amlot, P. L., Tharakan, G., Beǵent, R. H. J., & Chester, K. A. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601888 · Cited by 84
Hamann, P. R., Hinman, L. M., Beyer, C. F., Greenberger, L. M., Lin, C. J., Lindh, D., Menendez, A. T., Wallace, R., Durr, F. E., & Upeslacis, J. (2005) · Bioconjugate Chemistry · doi:10.1021/bc049795f · Cited by 81
Progress in immunoconjugate cancer therapeutics
Payne, G. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00057-6 · Cited by 76
Characterization of Site-Specific ScFv PEGylation for Tumor-Targeting Pharmaceuticals
Natarajan, A., Xiong, C.-Y., Albrecht, H., DeNardo, G. L., & DeNardo, S. J. (2004) · Bioconjugate Chemistry · doi:10.1021/bc0498121 · Cited by 73
Albrecht, H., Burke, P. A., Natarajan, A., Xiong, C.-Y., Kalicinsky, M., DeNardo, G. L., & DeNardo, S. J. (2003) · Bioconjugate Chemistry · doi:10.1021/bc030018+ · Cited by 72
Tumour-targeted chemotherapy with immunoconjugates of calicheamicin
Damle, N. K. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.9.1445 · Cited by 66
Boghaert, E. R., Sridharan, L., Armellino, D. C., Khandke, K. M., DiJoseph, J. F., Kunz, A., Dougher, M. M., Jiang, F., Kalyandrug, L. B., Hamann, P. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0037 · Cited by 66
Li, L., Olafsen, T., Anderson, A.-L., Wu, A. M., Raubitschek, A. A., & Shively, J. E. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025565u · Cited by 64
Self-citationSharkey, R. M., Hajjar, G., Yeldell, D., Brenner, A. J., Burton, J., Rubin, A. D., & Goldenberg, D. M. (2005) · PubMed · Cited by 64
Phase II Study of Dolastatin-10 as First-Line Treatment for Advanced Colorectal Cancer
Saad, E. D., Kraut, E. H., Hoff, P. M., Moore, D. F., Jones, D., Pazdur, R., & Abbruzzese, J. L. (2002) · American Journal of Clinical Oncology · doi:10.1097/00000421-200210000-00005 · Cited by 64
Pretargeting with Amplification Using Polymeric Peptide Nucleic Acid
Wang, Y., Chang, F., Zhang, Y., Liu, N., Liu, G., Gupta, S., Rusckowski, M., & Hnatowich, D. J. (2001) · Bioconjugate Chemistry · doi:10.1021/bc0100307 · Cited by 60
Rossi, E. A., Chang, C., Losman, M. J., Sharkey, R. M., Karacay, H., McBride, W., Cardillo, T. M., Hansen, H. J., Qu, Z., Horak, I. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1004-0020 · Cited by 50
Synthesis of an immunoconjugate of camptothecin
Walker, M. A., Dubowchik, G. M., Hofstead, S. J., Trail, P. A., & Firestone, R. A. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00707-7 · Cited by 47
Siemers, N. O., Kerr, D. E., Yarnold, S., Stebbins, M. R., Vrudhula, V. M., Hellström, I., Hellström, K. E., & Senter, P. D. (1997) · Bioconjugate Chemistry · doi:10.1021/bc9700751 · Cited by 47
Self-citationTumor Physiology and Antibody Delivery1
Jain, R. K. (2015) · Frontiers of radiation therapy and oncology · doi:10.1159/000417767 · Cited by 38
Mosure, K. W., Henderson, A. J., Klunk, L. J., & Knipe, J. O. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050655 · Cited by 36
Advances in antibody-directed enzyme prodrug therapy.
Sharma, S. K., Bagshawe, K. D., & Beǵent, R. H. J. (2005) · PubMed · Cited by 32
Technology evaluation: cantuzumab mertansine
Smith, S. (2004) · Current opinion in molecular therapeutics · Cited by 8
Lutz, R. J., Xie, H., Widdison, W. C., Wunderli, P. S., Steeves, R. M., Goldmacher, V. S., Lambert, J. M., & Chari, R. V. J. (2005) · Cancer Research · Cited by 6
Cited by
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.2.106 · Cited by 5,314
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
Sletten, E. M., & Bertozzi, C. R. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200900942 · Cited by 3,165
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
Kobayashi, H., Ogawa, M., Alford, R., Choyke, P. L., & Urano, Y. (2010) · Chemical Reviews · doi:10.1021/cr900263j · Cited by 2,200
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Metadata
- Authors
- Wu, A. M., & Senter, P. D.
- Venue
- Nature Biotechnology
- Published
- 2005-09-01
- Volume
- 23
- Issue
- 9
- Pages
- 1137-1146
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2048313558
- Cited by
- 1,052
- References
- 74
- FWCI
- 53.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.